Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | PTGES | O14684 | 3/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20233519 | 0.83 | HDAC6 (0.42) | MAPTHDAC6CA1CA2CA7 | |
| SCHEMBL12265783 | 0.79 | SMN1; SMN2 (0.67) | L3MBTL1POLBALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL14590706 | 0.78 | NPSR1 (0.52) | MAPTHDAC6L3MBTL1SMN1; SMN2KDM4E | |
| SCHEMBL17035934 | 0.77 | KDM4A (0.47) | L3MBTL1KDM4E | |
| SCHEMBL19318542 | 0.76 | CYP2C9 (0.51) | MAPTHDAC6CA1CA2CA7 | |
| SCHEMBL19318508 | 0.76 | RIPK1 (0.42) | MAPTHDAC6CA1CA2CA7 | |
| SCHEMBL25587531 | 0.76 | ADORA2A (0.48) | — | |
| SCHEMBL17057294 | 0.75 | SMN1; SMN2 (0.42) | POLBALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL25587529 | 0.75 | ADORA2A (0.45) | MAPTHDAC6RIPK1 | |
| SCHEMBL19318510 | 0.75 | RIPK1 (0.48) | MAPTHDAC6CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2023-09-07 | — | — | US | disclosed |
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2023-09-07 | — | — | US | disclosed |
| EP-4215530-A1 | ISOXAZOLINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS | FMC Corporation (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20230174538-A1 | Tricyclic heterocycles | MERCK PATENT GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| US-20230174538-A1 | Tricyclic heterocycles | MERCK PATENT GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| US-20210309652-A1 | ISOXAZOLINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS | FMC CORPORATION | 2021-10-07 | — | — | US | disclosed |
| US-9682998-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682998-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160362421-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2016-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | YAP1, TERF2IP, TEAD1 | MAPT 2472/4885HDAC6 1870/4885CA1 4865/4885 |
| US-20210309652-A1 | ISOXAZOLINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS | PRDX1, CYP4X1, RDX | MAPT 4027/4885HDAC6 935/4885CA1 2628/4885 |
| US-20160362421-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, CACNA1A, KCNH2 | MAPT 4552/4885HDAC6 848/4885CA1 1728/4885 |
| US-20230174538-A1 | Tricyclic heterocycles | YAP1, TEAD1, TERF2IP | MAPT 2572/4885HDAC6 1725/4885CA1 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.